New Options in the Management of Intractable ALK(+) Metastatic Non-Small-Cell Lung Cancer

Lung Cancer: Targets and Therapy- New Zealand

doi 10.2147/lctt.s50414

Full Text

Abstract

Available in

Categories

Date

August 1, 2014

Authors

Shirish Gadgeel

Publisher

Informa UK Limited

Related search

Nivolumab in Metastatic Non–Small Cell Lung Cancer

Journal of the Advanced Practitioner in Oncology

English

Brigatinib for ALK-positive Metastatic Non-Small-Cell Lung Cancer: Design, Development and Place in Therapy

Drug Design, Development and Therapy

Pharmaceutical Science

English

The Biology and Treatment of EML4-ALK Non-Small Cell Lung Cancer

European Journal of Cancer

Cancer Research

English

Tackling ALK in Non-Small Cell Lung Cancer: The Role of Novel Inhibitors

Translational Lung Cancer Research

English

The Treatment Choice Based on Radiographic Features for Metastatic Brain Tumors in ALK-Rearranged Non–small Cell Lung Cancer

International Journal of Radiation Oncology Biology Physics

Cancer Research

Nuclear Medicine

English

Systematic Review and Meta-Analysis of Selected Toxicities of Approved ALK Inhibitors in Metastatic Non-Small Cell Lung Cancer

English

Treating Patients With ALK-positive Non-Small Cell Lung Cancer: Latest Evidence and Management Strategy

Therapeutic Advances in Medical Oncology

English

Unmet Needs in the Treatment of Metastatic Non-Small-Cell Lung Cancer

European Oncology and Haematology

English

Differential Crizotinib Response Duration Among ALK Fusion Variants in ALK-Positive Non–Small-Cell Lung Cancer

Journal of Clinical Oncology

Cancer Research

English